Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Indy Hematology Review

H. Erba

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

Sarah Tasian

2024 Updates in AML

University of Colorado Division of Hematology

C. McMahon

Emerging Treatment Options for AML in 2024

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

A. Perl

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

UChicago Medicine 12th International Clinical Cancer Genomics Conference

L. Banaszak

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

Integrating Targeted Therapies in AML

Icahn School of Medicine at Mount Sinai

H. Kantarjian

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Fred Hutchinson Cancer Center

R. Cassaday